

## **AMENDMENTS TO THE CLAIMS:**

### **Listing of Claims**

Claims 1-27: Cancelled.

Claim 28 (Currently amended): A process for manufacturing a ~~substantially moisture stable, non-controlled release~~ pharmaceutical drug product having an active core, comprising the steps of:

A) mixing ethylcellulose, ~~polar an organic~~ solvent, ~~alcohol~~ and a surfactant to ~~make form~~ a moisture barrier, ~~non-controlled release pharmaceutical excipient-~~ coating solution;

B) mixing coating a drug substance with said ~~moisture barrier pharmaceutical excipient coating~~ solution to form ~~substantially moisture stable drug substance~~ said active core, wherein said coating solution is adapted to allowing normal release of said drug substance in a gastro-intestinal environment of a mammal;

C) coating the substantially moisture resistant drug substance of step B in a pharmaceutically acceptable coating forming a unit dosage form from said active core, wherein said unit dosage form optionally comprises one or more pharmaceutically acceptable excipients.

Claim 29 (Currently amended): The process of claim ~~[[28]]~~ 49, wherein said outer layer pharmaceutically acceptable coating comprises a gelatin capsule.

Claim 30 (Original): The process of claim 28, wherein said surfactant comprises polysorbate 80, and wherein said polysorbate 80 and said ethylcellulose are present in a ratio of approximately 1.00 : 0.165.

Claim 31 (Original): The process of claim 28, wherein said drug substance comprises paroxetine.

Claim 32 (Original): The process of claim 28, wherein said surfactant comprises polysorbate 80, and wherein said polysorbate 80 and said ethylcellulose are present in a ratio of approximately 1.00 : 0.165, and wherein said drug substance comprises paroxetine.

Claim 33 (Currently amended): A substantially moisture stable, ~~non-controlled release~~ pharmaceutical drug product comprising:

~~A) A substantially moisture stable, non-controlled release core comprising a drug substance paroxetine or a pharmaceutically acceptable salt thereof~~[[,]]; ethylcellulose; and a surfactant, the ethylcellulose and surfactant forming a coating for said paroxetine that is adapted to retarding degradation of said paroxetine while allowing normal release of said paroxetine in a gastro-intestinal environment of a mammal

~~B) An outer layer surrounding said core, said outer layer comprising a pharmaceutically acceptable material, said outer layer substantially free of said drug substance.~~

Claim 34 (Currently amended): The drug product of claim 33, wherein[[:]]

[[A)]] said surfactant comprises polysorbate 80, and wherein said polysorbate 80 and said ethylcellulose are present in a ratio of approximately 1.00 : [[0.165]] 1.65.

Claim 35 (Currently amended): The drug product of claim 33, ~~wherein: A) said drug substance comprises paroxetine~~ further comprising an outer layer surrounding said core, wherein said outer layer comprises pharmaceutically acceptable excipients and is substantially free of said paroxetine.

Claim 36 (Currently amended): The drug product of claim 33, wherein:

~~A) said drug substance comprises paroxetine, said surfactant comprise polysorbate 80, and wherein said polysorbate 80~~ said surfactant and said ethylcellulose are present in a ratio of approximately 1.00 : [[0.165]] 1.65.

Claim 37 (New): The drug product of claim 33, wherein said paroxetine comprises granules comprising paroxetine or a pharmaceutically acceptable salt thereof and wherein said coating optionally penetrates said paroxetine granules.

Claim 38 (New): The drug product of claim 37, wherein said surfactant comprises polysorbate 80.

Claim 39 (New): The drug product of claim 36, wherein said surfactant comprises polysorbate 80.

Claim 40 (New): The drug product of claim 35, wherein said paroxetine, coating, and outer layer form a unit dosage form of said drug product.

Claim 41 (New): The drug product of claim 40, wherein said unit dosage form is a tablet.

Claim 42 (New): The drug product of claim 41, wherein said tablet is optionally seal coated with one or more hydrophobic excipient.

Claim 43 (New): The drug product of claim 40, wherein said drug product is incorporated into a gelatin capsule.

Claim 44 (New): A substantially moisture stable pharmaceutical drug product comprising:

a substantially moisture stable active core comprising a drug substance coated with ethyl cellulose and a surfactant, wherein said coating is adapted to allowing normal release of said drug substance in a gastro-intestinal environment of a mammal; and

an outer layer surrounding said active core, wherein said outer layer comprising one or more pharmaceutically acceptable excipients and wherein said outer layer is substantially free of said drug substance.

Claim 45 (New): The drug product of claim 44, wherein the outer layer comprises an inactive gelatin capsule.

Claim 46 (New): The drug product of claim 44, wherein said drug substance is paroxetine hydrochloride.

Claim 47 (New): The drug product of claim 44, wherein the surfactant is polysorbate 80.

Claim 48 (New): The drug product of claim 48, wherein the said polysorbate 80 and said ethyl cellulose are present in a ratio of approximately 1.00:1.65.

Claim 49 (New): The process of claim 28, further comprising the step of forming an outer layer surrounding said active core, wherein said outer layer comprising one or more pharmaceutically acceptable excipients and wherein said outer layer is substantially free of said drug substance.

Claim 50 (New): The process of claim 28, further comprising the step of:

D) combining said coated drug substance and said one or more pharmaceutically acceptable excipients; and

E) granulating the combination formed in step D),

wherein the step of forming a unit dosage form comprises using compression to form a tablet.

Claim 51 (New): The process of claim 28, further comprising the step of:

D) combining said coated drug substance and said one or more pharmaceutically acceptable excipients; and

E) granulating said combination formed in step D),

wherein the step of forming a unit dosage form comprises incorporating said granulated combination into a hard gelatin capsule.